Spero Therapeutics snags $51.7 mln in GV-led round
Cambridge, Massachusetts-based Spero Therapeutics LLC, a biopharmaceutical company focused on developing treatments for bacterial infections, has closed $51.7 million in Series C financing. GV led the round with participation from other investors that included RA Capital Management, Rock Springs Capital, Atlas Venture, MRL Ventures Fund, Lundbeckfonden Ventures, The Kraft Group and Osage University Partners.
8 March 2017•1 min read
